Last Thursday (June 28), a medical cannabis company with business in the US and Canada received a rating and one-year price predictions from one of the leading cannabis banking firms.
Canaccord Genuity started its coverage of Sunniva (CSE:SNN) off by slapping the company with a “Speculative Buy” rating on its stock and a one year price target of C$7.80. Sunniva’s previous closing price on Tuesday (July 3) was C$8.10.
Sunniva owns a late stage applicant to legally grow medical cannabis in Canada, with the plans to develop a 700,000 square feet greenhouse facility–the Sunniva Canada Campus– with a target production of 100,000 kilograms of cannabis product at this facility, according to the report.
In addition to the Suniva Canada Campus the company Sunniva is also focused in the California market with the construction of a greenhouse facility expected to produce an additional 100,000 kilograms of cannabis per year.
“Although we believe our individual valuations are built on relatively conservative assumptions, the core value driver of our model rests in the assumed market penetration Sunniva will ultimately be able to secure in California and Canada,” the note from Canaccord analyst Matt Bottomley said.
As part of its Q1 financial results, Sunniva indicated it had obtained a confirmation of readiness from Health Canada about its licensed producer (LP) application.
The company also owns Natural Health Services, a cannabis clinic operator with seven locations in Canada offering patient consultations and has a 95,000 patient base, according to the note.
In February Sunniva signed a supply agreement with Canopy Growth (TSX:WEED;NYSE:CGC) to provide 45,000 kilograms of dried cannabis annually. Leith Pedersen, president of Sunniva, said by making this partnership the company was “de-risking” its business model.
According to the data presented by the report the company holds a “SOTP” (sum-of-the-parts) valuation of C$13.08 per share.
Bottomley wrote he believes Sunniva will have to “secure a portion of its market share in its own branded products to cement a longer-term market position and to safeguard against margin compression.”
Canaccord cited the potential for the company to not achieve its projected production capacity as a significant risk for Sunniva’s Canadian operations.
US interest for the company adds value due to right momentum in the country
Despite holding an interest in the often volatile US cannabis market, Canaccord believes the momentum is swinging right for the drug at the moment, particularly in California with the legalization of adult-use cannabis this year.
As a whole, cannabis companies with US assets have been forced to raise capital in the Canadian Securities Exchange (CSE) due to the lighter restrictions around the interests below the border.
During panel at the Vancouver edition of the International Cannabis Business Conference (ICBC) Anna Serin, director of listings development for the CSE, told the crowd over the past year 58 percent of the capital raised by CSE-listed companies, close to C$2 billion, was in cannabis.
Since the report was issued to investors last Thursday the company’s stock has increased in value by 4.65 percent and is finished Wednesday’s (July 4) trading session at a price of C$8.10 per share.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).